$IBRX (+3.6% pre) ImmunityBio (IBRX) Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients - SI ooc.bz/l/76813
4
4 Likes